Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Context Therapeutics Inc. (CNTX)

Context Therapeutics updates August 2026 corporate presentation for investor meetings

Neutral Impact 1 of 5 other Written later

Context Therapeutics filed an updated corporate presentation dated August 2026 as Exhibit 99.1 to a Form 8-K on August 5, 2026, for use in meetings with investors and analysts. The filing is furnished under Regulation FD and contains no financial results, guidance, or new financing terms, and it lists the company's clinical timelines for its two T cell engager programs.

Key points

  • Updated corporate presentation filed as Exhibit 99.1 on August 5, 2026; the filing is furnished, not filed, under Section 18 of the Exchange Act.
  • CTIM-76 (Claudin 6 x CD3) has FDA Fast Track Designation for platinum-resistant ovarian cancer; the presentation anticipates starting a Phase 1b study in Q1 2027.
  • CT-202 (Nectin-4 x CD3) Phase 1a first patient dosing is anticipated in Q3 2026, with initial data expected in 2H 2027.
  • The presentation reports a 29% confirmed objective response rate in 7 RECIST-evaluable platinum-resistant ovarian cancer patients at target doses, as of May 29, 2026.

The filing

CompanyContext Therapeutics Inc. (CNTX)
Form8-K, current report
Filed with the SECAug 5, 2026, 4:16 PM ET
Accession number0001628280-26-053378

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.